Integra LifeSciences Sees Revenue Guidance Miss, Forecasting 2.7% Sales Drop
Last quarter Integra LifeSciences reported $402.1 million in revenue, a 5.6% year-on-year rise, but its next-quarter revenue guidance significantly missed analysts’ forecasts. Ahead of its Q4 report, the consensus projects a 2.7% sales decline versus peers delivering 18.8% and 15% revenue gains.
1. Last Quarter Financial Performance
Integra LifeSciences posted $402.1 million in Q3 revenue, marking a 5.6% year-on-year increase but falling short of analyst expectations. This miss continued a pattern of revenue disappointments, suggesting persistent demand softness in its surgical equipment and consumables divisions.
2. Next-Quarter Guidance
Management’s outlook for the upcoming quarter forecasts a 2.7% year-on-year revenue decline, a stark reversal from last year’s 11.5% gain. The weak guidance highlights potential headwinds from reduced hospital spending and inventory adjustments.
3. Peer Revenue Trends
Within the healthcare equipment and supplies segment, Intuitive Surgical delivered 18.8% year-on-year revenue growth and Envista achieved a 15% increase, both topping estimates. These strong peer performances underscore the company-specific nature of Integra’s guidance shortfall.
4. Analyst Sentiment
Analysts have largely maintained their estimates in the past 30 days, assigning an average price target of $15.50 against the prevailing market price. Despite recent sector weakness—stocks down 1.9% on average over the last month—Integra’s shares rose 5.7%, reflecting divergent investor expectations ahead of results.